The Cambridge-based biotechnology firm is prioritizing the initiation of its PARAGON study, which has received FDA clearance to enroll 300 participants. However, the capital-intensive nature of the trial has forced leadership to seek external support, including potential pharmaceutical partnerships and non-dilutive funding, rather than relying solely on traditional equity raises. Ben-Noon emphasized that the company is specifically targeting partners who can provide strategic value alongside financial resources.

While waiting for the necessary funding to launch the U.S.-based trial, NeuroSense is leveraging existing data from its Phase 2b PARADIGM study to pursue early market entry. The company expects to submit a New Drug Submission to Health Canada in December 2026, aiming to bypass the multi-year wait associated with finishing new large-scale clinical trials. Simultaneously, management is addressing Nasdaq listing deficiencies, specifically the minimum bid price requirement. Shareholders will soon vote on a proposal to authorize a reverse stock split at a ratio between 1:4 and 1:40, though the company maintains this would serve as a final resort if other compliance measures fail.